Sledge Jr. GW, et al. MONARCH 2: Overall survival of abemaciclib plus fulvestrant in patients with HR+, HER2- advanced breast cancer. LBA6_PR. ESMO 2019. 28 sep.-1 okt. 2019, Barcelona, Spanje.
Fulvestrant plus anastrozol bij gemetastaseerd mammacarcinoom: langetermijnresultaten
jun 2019 | Borstkanker